Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors
Cell Reports · 2023-04 · 42 (4) · 112297
DOI: 10.1016/j.celrep.2023.112297 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2023-04. Verfasst von Ralph Tiedt und 20 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Institutes for BioMedical Research Basel, Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.
- Novartis Institutes for BioMedical Research, Genomics Institute of the Novartis Research Foundation, La Jolla, CA, USA.
- Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA. Electronic address: matt.niederst@novartis.com.
- Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.
Förderung
- Novartis Institutes for BioMedical Research Basel
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Tiedt, R., King, F. J., Stamm, C., Niederst, M. J., Delach, S., Zumstein-Mecker, S., Meltzer, J., Mulford, I. J., Labrot, E., Engstler, B. S., Baltschukat, S., Kerr, G., Golji, J., Wyss, D., Schnell, C., Ainscow, E., Engelman, J. A., Sellers, W. R., Barretina, J., …, & Porta, D. G. (2023). Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. Cell Reports, 42(4), 112297. https://doi.org/10.1016/j.celrep.2023.112297
Vancouver
Tiedt R, King FJ, Stamm C, Niederst MJ, Delach S, Zumstein-Mecker S, et al. Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. Cell Reports. 2023;42(4):112297. doi:10.1016/j.celrep.2023.112297
BibTeX
@article{Tiedt2023,
author = {Tiedt, Ralph and King, Frederick J and Stamm, Christelle and Niederst, Matthew J and Delach, Scott and Zumstein-Mecker, Sabine and Meltzer, Jodi and Mulford, Iain J and Labrot, Emma and Engstler, Barbara Schacher and Baltschukat, Sabrina and Kerr, Grainne and Golji, Javad and Wyss, Daniel and Schnell, Christian and Ainscow, Edward and Engelman, Jeffrey A and Sellers, William R and Barretina, Jordi and Caponigro, Giordano and Porta, Diana Graus},
title = {Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors},
journal = {Cell Reports},
year = {2023},
volume = {42},
number = {4},
pages = {112297},
doi = {10.1016/j.celrep.2023.112297}
}
EUVIMED